 Chardan Research initiated coverage on Avidity Biosciences Inc NASDAQ: RNA with a Buy rating and a price target of 29 and Dyne Therapeutics Inc NASDAQ: DYN with a Buy rating and a price target of 17. We believe that Avidity and Dyne are an. 